New hope for stomach cancer patients with abdominal spread

NCT ID NCT07556640

Recruiting now Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of drugs (LM-302, S-1, and intraperitoneal paclitaxel) with or without another drug (cadonilimab) in people with a specific type of advanced stomach cancer (Claudin 18.2-positive) that has spread to the lining of the abdomen. The goal is to see if these treatments improve survival and control the disease. About 74 adults will participate, and the study is currently recruiting.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal adenocarcinoma gastroesophageal junction adenocarcinoma peritoneal carcinomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER STAGE IV GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA PERITONEAL METASTASES FROM GASTRIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Ruijin Hospital Shanghai Jiao Tong University School of Medicine
RECRUITING

Shanghai, Huangpu District, 200025, China

Contact Phone: •••-•••-•••• Email: •••••@•••••